The region has seen serious spikes in venture capital funding in the last decade — and more of our local firms are benefiting.
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its licensee for RGN-137, GtreeBNT Co., Ltd., received a positive response from the U.S. FDA for its Phase 3 clinical trial design for RGN-137 to treat epidermolysis bullosa (“EB”). RGN-137 is a dermal wound healing gel that incorporates Thymosin beta 4 (“Tβ4”) as the active pharmaceutical ingredient. GtreeBNT is planning to enter into the Phase 3 trial in the U.S. during the third quarter of 2017.
PGDx launched in 2010 to bring innovative genetic analyses to cancer researchers, physicians and patients. PGDx uses cutting-edge next-generation sequencing and analysis techniques to identify mutations in patients’ tumors and facilitate the development of personalized treatment plans as well as novel basic science discoveries. In addition, PGDx has developed exciting liquid biopsy technology that uses patient-specific tumor alterations to create a simple blood test that will enable non-invasive tumor detection and monitoring. PGDx is composed of talented individuals with a variety of scientific backgrounds that are dedicated to advancing medicine through genomic technologies.
When California voters approved US$3 billion in funding for stem-cell research in 2004, biologists flocked to the state, and citizens dreamed of cures for Parkinson’s disease and spinal-cord injuries. Now, the pot of money — one of the biggest state investments in science — is running dry before treatments have emerged, raising questions about whether Californians will pour billions more into stem-cell research.
The lupus treatment landscape could soon welcome an entrant if a first-in-class anti-interferon monoclonal antibody (mAb) continues to hit clinical-trial targets. AstraZeneca and its biologics R&D branch, MedImmune, are developing anifrolumab, an investigational monoclonal antibody that blocks type 1 interferons to treat moderate to severe systemic lupus erythematosus (SLE).
The Johns Hopkins University announced today the opening of its state-of-the-art innovation hub, FastForward 1812. The 23,000-square-foot space near Johns Hopkins’ flagship hospital and schools of medicine, public health and nursing provides Baltimore’s burgeoning innovation ecosystem and area startups sought-after office, co-working and wet lab space to accommodate a variety of startups.
Epigenomics AG (FSE: ECX; OTCQX: EPGNY) (“Epigenomics” or “Company”), Cathay Fortune International Company Limited (“CFIC”) and Blitz F16-83 GmbH (in the future Summit Hero Holding GmbH, “Bidder”), a subsidiary of CFIC, have tonight entered into a business combination agreement (“BCA”) regarding the takeover of Epigenomics by the Bidder. Other than by CFIC, the Bidder will also be indirectly owned by the currently largest shareholder of Epigenomics, Biochain, the strategic partner of Epigenomics and a subsidiary of Team Curis Group.
AstraZeneca today marks a key milestone in its successful move to Cambridge, UK, with the ‘topping out’ of its new, state-of-the-art, strategic R&D centre and global corporate headquarters at the heart of the Cambridge Biomedical Campus (CBC). The Company, including its biologics research and development arm, MedImmune, already has 2,000 employees actively engaged in the city’s vibrant scientific, academic, clinical and business community. Occupation of the site will begin in stages in 2018.
BeneVir Biopharm, Inc., a biotechnology company developing oncolytic immunotherapies for the treatment of cancer, announced today that the U.S. Patent and Trademark Office has issued US Patent No. 9,623,059, entitled “Oncolytic Herpes Simplex Virus and Therapeutic Uses Thereof”, covering the composition of matter for Stealth-1H, BeneVir’s lead oncolytic immunotherapy, as well as other platform assets. BeneVir is a portfolio company within Pansend Life Sciences, a subsidiary of HC2 Holdings, Inc. (NYSE MKT: HCHC)
If you are part of the Maryland entrepreneurial community please take a few minutes to complete our survey.
We are interested in the opinions of people like you regarding TEDCO (Maryland Technology Development Corporation) and its effectiveness in the Maryland Entrepreneurial Ecosystem. By answering the following questions, you will become a valuable part of an important study to evaluate and improve Maryland’s position in growing the entrepreneurial technology community within the state.